Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University Hospital of North Norway
With
Norwegian Cancer Society
Northern Health Authority
St. Olavs Hospital
Copenhagen University Hospital, Rigshospitalet
Odense University Hospital
Oslo University Hospital
University of Tromso
The main aim is to validate the most promising T-cell marker candidates from earlier studies in a prospective multicenter study to establish a prognostic TNM-Immunoscore.
The investigators will include around 1000 stage I-IIIA patients from various centers in Scandinavia. The investigators will also collect demographic and clinicopathological data, blood and tissues in a database and biobank. Candidate T-cell markers will be analyzed by immunohistochemistry for validation and by other methods for exploration of their impact on prognosis
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
resectable NSCLC
Age 18 and above
no other malignancy last 5 years
informed consent
You may not be if
multiple tumor foci
preoperative chemo- or radiotherapy
non-NSCLC histology
no tissue available for study
metastasis
Clareo Health | Clinical Implementation of TNM-immunoscore in Resected Non-small Cell Lung Cancer
